• No results found

Leukocyte Typing II VOLUME 2. Human B Lymphocytes

N/A
N/A
Protected

Academic year: 2021

Share "Leukocyte Typing II VOLUME 2. Human B Lymphocytes"

Copied!
18
0
0

Loading.... (view fulltext now)

Full text

(1)

Leukocyte Typing II

VOLUME 2

(2)

Leukocyte Typing II

Volume 1 Human T Lymphocytes

Volume 2 Human B Lymphocytes

(3)

Leukocyte Typing

II

VOLUME 2

Human B Lymphocytes

Edited by

Ellis L. Reinherz Barton F. Haynes

Lee M. Nadler Irwin D. Bernstein

With 134 Illustrations

Springer -Verlag

(4)

EUis L. Reinherz, M.D., Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115 U.S.A.

Barton F. Haynes, M.D., Department of Medicine, Duke University School of Medicine, Durham, NC 27710 U.S.A.

Lee M. Nadler, M.D., Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115 U.S.A.

Irwin D. Bernstein, M.D., Program in Pediatric Oncology, Fred Hutchinson Can-cer Research Center, Seattle, WA 98104 U.S.A.

Library of Congress Cataloging in Publication Data Main entry under title:

Leukocyte typing II.

Papers presented at the Second International

Workshop on Human Leukocyte Differentiation Antigens, held in Boston, Sept. 17-20, 1984.

Includes bibliographies and indexes.

Contents: v. I. Human T lymphocytes-v. 2. Human B lymphocytes-v. 3. Human myeloid and hematopoietic cells.

I. Leucocytes-Classification-Congresses. 2. Histocompatibility testing-Congresses. 3. Tissue specific antigens-Analysis-Congresses. I. Reinherz, Ellis L. II. International Workshop on Human

Leukocyte Differentiation Antigens (2nd: 1984 : Boston, Mass.) III. Title: Leukocyte typing 2. IV. Title:

Leukocyte typing two.

QRI85.8.L48L48 -1985 616.07'9 85-22229 © 1986 by Springer-Verlag New York Inc.

All rights reserved. No part of this book may be translated or reproduced in any form without written permission from Springer-Verlag, 175 Fifth Avenue, New York, New York 10010, U.S.A.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone.

While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Permission to photocopy for internal or personal use, or the internal or personal use of specific clients, is granted by Springer-Verlag New York Inc. for libraries registered with the Copyright Clearance Center (CCC), provided that the base fee of $0.00 per copy, plus $0.20 per page is paid directly to CCC, 21 Congress Street, Salem, MA 01970, U.S.A. Special requests should be addressed directly to Springer-Verlag New York, 175 Fifth Avenue, New York, New York 10010, U.S.A.

Typeset by Bi-Comp Inc., York, Pennsylvania.

9 8 7 6 5 4 3 2 I

ISBN-13: 978-1-4612-9328-6 e-ISBN-13: 978-1-4612-4848-4 DOl: 10.1007/978-1-4612-4848-4

(5)

Preface

The Second International Workshop on Human Leukocyte Differentia-tion Antigens was held in Boston, September 17-20, 1984. More than 350 people interested in leukocyte differentiation agreed to exchange reagents and participate in this joint venture. All in all, in excess of 400 antibodies directed against surface structures on T lymphocytes, B lymphocytes, and myeloid-hematopoietic stern cells were characterized. Because of the enormous quantity of serologic, biochemical, and functional data,

Leuko-cyte Typing II has been divided into three volumes.

These books represent the written results of workshop participants. They should be helpful to both researchers and clinicians involved in scientific endeavors dealing with these broad fields of immunobiology. To those who delve into the various sections of the volumes, it will become evident that the work speaks for itself.

I am deeply indebted to the section editors, Barton F. Haynes, Volume

1, Human T Lymphocytes, Lee M. Nadler, Volume 2, Human B

Lympho-cytes, and Irwin D. Bernstein, Volume 3, Human Myeloid and

Hemato-poietic Cells for their major contributions in planning, executing, and summarizing the workshop, as well as council members John Hansen, Alain Bernard, Laurence Boumsell, Walter Knapp, Andrew McMichael, Cesar Milstein, and Stuart F. Schlossman. I would also like to thank the National Institutes of Health, World Health Organization, and Interna-tional Union of Immunological Societies for making this meeting possible. Needless to say, I am most grateful to all of my colleagues who contrib-uted to this effort and helped to accelerate the characterization of human immunobiology through their endeavors.

(6)

Contents

I. Introduction

1. B Cell/Leukemia Panel Workshop: Summary and Comments

L.M. Nadler 3

II. Serologic Specificity of B Cell/Leukemia Monoclonal

Anti-bodies

2. Analysis of the B Cell/Leukemia Workshop Monoclonal Antibodies Using an Immunoenzymatic Staining Assay and a Radioimmunoassay on Cells B. Darken,

G. Moldenhauer, A. Pezzutto, R. Schwartz, S. Kiesel,

W. Hunstein 47

3. Analysis of Ten B Lymphocyte-Specific Workshop Monoclonal Antibodies G. Moldenhauer, B. Darken,

R. Schwartz, A. Pezzutto, J. Knops, GJ. Hiimmerling 61

4. Screening of Workshop "B" Series Antibodies by

Radioimmunobinding to Human Leukocyte Cell Lines and to Cells from Human Lymphoid Tumors C.M. Steel,

P. Elder, K. Guy 69

5. Expression of Lymphocyte Differentiation Antigens in Immunodeficiency Diseases T.F. Tedder, L.T. Clement,

MJ. Crain, M.D. Cooper 79

6. Use of Two Monoclonal Anti-Human B Cell Antibodies in the Study of Early B Cell Differentiation A. Raghavachar,

S.F. Goldmann, B. Kubanek 87

7. Characterization of a Human B Lymphocyte-Specific Antigen Defined by Monoclonal Antibodies HD6 and

(7)

viii Contents

HD39 G. Moldenhauer, B. Darken, R. Schwartz,

A. Pezzutto, GJ. Hiimmerling 97

8. Six Distinct Antigen Systems of Human B Cells as Defined by Monoclonal Antibodies Y. Ishii, T. Takami, H. Yuasa,

T. Takei, Y. Kokai, K. Kikuchi 109

9. B-Cl, B-C2, B-C3: Monoclonal Antibodies against B Cell Differentiation Antigens I. Anegon, R. Vi/ella, T. Gallart,

C. Cuturi, L. Borche, J. Mila, J. Vives 121

10. Human B Cells: Is FMC7 a Marker for Relatively Mature B Cells or Does It Define a Population Equivalent to the

LyB5-Negative Mouse B Cells? H. Zola 141

11. Spontaneous Mouse Erythrocyte Rosette Formation

(M-RFC) with Human B Lymphocytes: Diagnostic Value in B-Lymphoproliferative Diseases and Lack of Relationship to B Cell Protocol Monoclonal Antibodies P. Hokland, K. Meyer, I.M. Fastrup

III. Biochemical Analysis of Antigens Defined by the Workshop B Cell/Lenkemia Panel

12. Human B Cell Surface Molecules Defined by an Interna-tional Workshop Panel of Monoclonal Antibodies

147

E.A. Clark, D. Einfeld 155

13. Structural Analysis of Cell Surface Molecules Recognized by Leukemic Cell/B Cell Panel Antibodies T. W. LeBien,

J.G. Bradley, J.L. Platt, SJ. Pirruccello 169

14. Biochemical Analysis of Antigens Recognized by Workshop B Series Antibodies, Using "Western Blotting"

B.B. Cohen, M. Moxley, P. Elder, K. Guy, C.M. Steel 177

15. Human B Cell Antigens Detected by the Workshop

Antibodies: A Comparison of Serological and Immunochem-ical Patterns K. Horibe, R. W. Knowles 187

16. Further Evidence that the Human Differentiation Antigen p24 Possesses Activity Associated with Protein Kinase

T.F. Zip/, G.R. Antoun, G.J. Lauzon, B.M. Longenecker 203

17. Clustering of Anti-Leukemia and Anti-B Cell Monoclonal

Antibodies A.M. Ravoet, A.M. Lebacq-Verheyden 213

18. A Structurally Novel Human B Cell Surface Molecule

(8)

Contents ix

19. Human Neutrophils Synthesize Different Forms of the Common Acute Lymphoblastic Leukemia Antigen

R.T. McCormack, J.G. Bradley, T. W. LeBien 235

IV. Immunohistochemical Analysis of B Cell/Leukemia Panel Monoclonal Antibodies

20. Immunohistochemical Analysis of Monoclonal Anti-B Cell

Antibodies D. Y. Mason, H. Ladyman, K.C. Gatter 245

21. Analysis of Band L Workshop Antibodies on Sections of Normal and Neoplastic Lymphoid Tissue and Cell Lines

I.C.M. MacLennan, P.D. Nathan, G.D. Johnson, M. Khan, L. Walker, N.R. Ling 257

22. Immunohistol9gical Analysis of Tissue Specificity of the Fifty-two Workshop Anti-B Lymphocyte Monoclonal

Antibodies G. Pallesen 277

23. Reactivity of Monoclonal Antibodies of the Band L Series with Follicular Dendritic Cells in Tissue Sections and with Lymphoblastoid Cell Lines G.D. Johnson,

I.C.M. MacLennan, N.R. Ling, D.L. Hardie,

P.D. Nathan, L. Walker 289

24. The Staining of a Panel of Routine Diagnostic Tissue Biopsies with the Workshop "L" Series Antibodies

D.B. Jones, K.M. Britten, D.H. Wright

25. Immunohistochemical Reactivity of Anti-B Cell Monoclonal Antibodies in Thymus, Lymph Node, and Normal Skin

E. Berti, C. Parravicini, G. Cattoretti, D. Delia,

299

F. de Braud, M. Cusini 313

26. Report to Second International Workshop on Human Leukocyte Differentiation Markers: Boston, 1984. Tissue Localization of B Cell and Leukemic Reagents (Special Studies) N. Kraft, P.S. Giddy, W. W. Hancock,

R.C. Atkins 319

V. Expression of B Cell/Leukemia Panel on Leukemias and Lymphomas

27. Quantitative Phenotypes of B Chronic Lymphocytic Leukemia B Cells Established with Monoclonal Antibodies from the B Cell Protocol P. Poncelel,

(9)

x Contents

28. Analysis of Workshop "L" Series Antibodies: Radioimmunobinding and Biochemical Studies

C.M. Steel, B.B. Cohen, P. Elder, M. Moxley, K. Guy 345

29. Subclassification of Leukemia Using Monoclonal Antibodies G.R. Pilkington, G.T.H. Lee,

P.M. Michael, O.M. Garson, N. Kraft, R.C. Atkins, D.G. Jose

30. Immunological Classification of "Unclassifiable" Acute Leukemia F. Herrmann, B. Darken, A. Gatzke,

353

W.D. Ludwig 367

31. Age Predilection of Distinct Phenotypically Defined Subgroups of N on-T Cell ALL: Studies Using B

Cell-Restricted or -Associated Monoclonal Antibodies in 359 Patients P. Herrmann, B. Darken, W.D. Ludwig,

H. Riehm 377

32. Heterogeneity of B-CLL Cells Defined by Monoclonal Antibodies N. Genetet, D. Bourel, B. Grosbois,

G. Merdrignac, M. Marty, R. Fauchet, F. Lancelin,

R. Leblay, B. Genetet 385

33. HD37 Monoclonal Antibody: A Useful Reagent for Further Characterization of "Non-T, Non-B" Lymphoid Malignancies A. Pezzutto, B. Darken, A. Feller,

G. Moldenhauer, R. Schwartz, P. Wernet, E. Thiel,

W. Hunstein 391

34. Characterization of Burkitt's Lymphoma Cell Lines with Monoclonal Antibodies Using an ELISA Technique

J.T. Sandlund, J. Kiwanuka, G.E. Marti, W. Goldschmidts,

I. T. Magrath 403

VI. Functional Significance of Human B Cell/Leukemia Antigens

35. Human B Cell Populations Defined by the Bl and B2 Antigens K.C. Anderson, A. W. Boyd, D.C. Fisher,

J.F. Daley, S.P. Schlossman, L.M. Nadler 413

36. Phenotypic Changes Occurring during in vitro Activation of

Human Splenic B Lymphocytes A. W. Boyd, A.S. Freedman, K.C. Anderson, D.C. Fisher,

J.C. Horowitz, J.P. Daley, S.F. Schlossman, L.M. Nadler 429

37. Antigenic Changes of the B Cell Panel of the Second International Workshop on Human Leukocyte Differentiation Antigens with in vitro Activation

(10)

Contents xi

A.S. Freedman, A. W. Boyd, D.C. Fisher, S.F. Schlossman,

L.M. Nadler 443

38. Activation of Human B Cells with Monoclonal Antibody to the Bp32 Cell Surface Polypeptide E.A. Clark, G. Shu,

J.A. Ledbetter 455

39. B Lymphocyte Surface Antigens Involved in the Regulation of Immunoglobulin Secretion J. Golay, F. Rawle,

P. Beverley 463

40. Inhibition of Immunoglobulin Secretion, But Not Immunoglobulin Synthesis, by a Monoclonal Antibody

S. Pittaluga, J. Cossman, J.B. Trepel, L.M. Neckers 473

41. Monoclonal Antibody AB1 Identifies a Human B Cell Activation Antigen and Inhibits Growth Factor-Dependent Human B Cell Proliferation L.K.L. Jung, S.M. Fu,

J. Morgan, A.L. Maizel 483

42. Detection and Functional Studies of IL-2 Receptors on Activated Human B Cells L.K.L. Jung, T. Hara,

S.M. Fu 491

43. The C3d Receptor Identified by the HB-5 Monoclonal Antibody: Expression and Role as a Receptor for

Epstein-Barr Virus T.F. Tedder, L.T. Clement, J.J. Weis,

D.T. Fearon, M.D. Cooper 499

44. The B Cell-Restricted Glycoprotein (B2) Is the Receptor for Epstein-Barr Virus L.M. Nadler, A. W. Boyd, E. Park,

K.C. Anderson, D.C. Fisher, B. Slaughenhoupt,

D.A. Thorley-Lawson, S.F. Schlossman 509

45. Monoclonal Antibody-Defined Cell Surface Molecules Regulate Lymphocyte Activation D.R. Howard,

A.C. Eaves, F. Takei 519

46. TPA-Induced Modulation of B Cell Differentiation Antigens Defined by Monoclonal Antibodies (HD6, HD28, HD37, HD39) R. Schwartz, G. Moldenhauer, B. Darken,

A. Pezzutto, F. Momburg, V. Schirrmacher 527

47. Functional Studies of p24: Platelet Aggregation Inhibition by Fab Monomers of BA-2 J.E. Brown, J.G. White,

R.D. Hockett, Jr., K.R. Hagert, J.H. Kersey 541

(11)

Contributors

Kenneth C. Anderson Division of Tumor Immunology, Dana-Farber

Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Ignacio Anegon Servicio de Inmunologfa, Hospital Clfnic i Provincial,

08036 Barcelona, Spain

Gamil R. Antoun Department of Pediatrics and the Tom Baker Cancer

Centre, University of Calgary, Calgary, Alberta, Canada T2N 4N1

Robert C. Atkins Nephrology Department, Prince Henry's Hospital,

Melbourne, Australia

Emilio Berti First Department of Dermatology, University of Milan,

Milan, Italy

Peter Beverley ICRF Human Tumor Immunology Group; School of

Medicine, University College London, London WClE 6JJ, U.K.

Luis Borche Servicio de Immunologfa, Hospital Clinic i Provincial,

08036 Barcelona, Spain

D. Bourel Groupe Universitaire de Recherche en Immunologie

Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

Andrew W. Boyd Division of Tumor Immunology, Dana-Farber Cancer

Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115 U.S.A.

J. Garrett Bradley Department of Laboratory Medicine/Pathology, U ni-versity of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

K.M. Britten University Department of Pathology, General Hospital

Southampton S09 4XY, U.K.

Jo Ellen Brown University of Minnesota, Minneapolis, Minnesota

55455, U.S.A.

Pierre Carayon Immunotoxin Project, Research Center Clin-Midy,

(12)

xiv Contributors

Giorgio Cattoretti National Cancer Institute of Milan, Milan, Italy Edward A. Clark Department of Microbiology and Immunology,

Uni-versity of Washington, Seattle, Washington 98195, U.S.A.

Loran T. Clement Cellular Immunobiology Unit, Tumor Institute,

Uni-versity of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.

B.B. Cohen Medical Research Council, Clinical and Population

Cytoge-netics Unit, Western General Hospital, Edinburgh, U.K.

Max D. Cooper Cellular Immunobiology Unit, Tumor Institute,

Univer-sity of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.

Jeffrey Cossman Laboratory of Pathology, National Cancer Institute,

National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Marilyn J. Crain Cellular Immunobiology Unit, Tumor Institute,

Uni-versity of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.

Marco Cusini First Department of Dermatology, University of Milan,

Milan, Italy

Cristina Cuturi Servicio de Inmunologfa, Hospital Clinic i Provincial,

08036 Barcelona, Spain

John F. Daley Division of Tumor Immunology, Dana-Farber Cancer

Inl'titute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Filippo de Braud National Cancer Institute of Milan, Milan, Italy Domenico Delia National Cancer Institute of Milan, Milan, Italy Bernd Dorken Medizinische U niversitats-Poliklinik, D-6900

Heidel-berg, F.R.G.

Allen C. Eaves Terry Fox Laboratory, B.C. Cancer Research Centre,

Vancouver, British Columbia, Canada

David Einfeld Immunobiology Group, Genetic Systems Corporation,

Seattle, Washington 98121, U.S.A.

Patricia Elder Medical Research Council Clinical and Population

Cyto-genetics Unit, Western General Hospital, Edinburgh, U.K.

lise Marie Fastrup The University Department of Medicine and

Hema-tology, Aarhus Amtssygehus, Denmark DK-8000

R. Fauchet Groupe Universitaire de Recherche en Immunologie

Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

Douglas T. Fearon Department of Medicine, Harvard Medical School,

Department of Rheumatology & Immunology, Brigham and Wom-en's Hospital, Boston, Massachusetts 02115, U.S.A.

A. Feller Pathologisches Institute der Universitat Kiel, KieI, F.R.G. David C. Fisher Division of Tumor Immunology, Dana-Farber Cancer

Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

(13)

Contributors xv Arnold S. Freedman Division of Tumor Immunology, Dana-Farber Can-cer institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Shu Man Fu Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, U.S.A.

Teresa Gallart Servicio de Inmunologfa, Hospital Clinic i Provincial, 08036 Barcelona, Spain

O. Margaret Garson Immunogenetics Research Unit, Cancer Institute, Melbourne, Australia 3000

K.C. Gatter Department of Haematology, John Radcliffe Hospital, Ox-ford OX3 9DU, U.K.

A. Gatzke Abt. Hamatologie, Klinikum Steglitz, Freie Universitat Berlin, Berlin, F.R.G.

B. Genetet Groupe Universitaire de Recherche en Immunologie Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

N. Genetet Groupe Universitaire de Recherche en Immunologie Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

Peter S. Giddy Nephrology Department, Prince Henry's Hospital, Mel-bourne, Australia

Josee Golay ICRF Human Tumor Immunology Group, School of Medi-cine, University College London, London WCIE 611, U.K. Shraga F. Goldmann Red Cross Blood Bank Ulm, Department of

Trans-fusion Medicine, University of Ulm, D-7900 Ulm, F.R.G.

Walter Goldschmidts Pediatric Branch, Clinical Oncology Program, Di-vision of Cancer Treatment, National Cancer Institute, National In-stitutes of Health, Bethesda, Maryland 20205, U.S.A.

B. Grosbois Groupe Universitaire de Recherche en Immunologie Fon-damentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

Keith Guy Medical Research Council Clinical and Population Cytoge-netics Unit, Western General Hospital, Edinburgh, U.K.

Gunter J. Hammerling Institut fUr Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G. Kathleen R. Hagert University of Minnesota, Minneapolis, Minnesota

55455, U.S.A.

Wayne W. Hancock Nephrology Department, Prince Henry's Hospital, Melbourne, Australia

Toshiro Hara Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, U.S.A.

D.L. Hardie Department of Immunology, The Medical School, U niver-sity of Birmingham, Birmingham BI5 2TJ, U.K.

F. Herrmann Abt. Haematologie, Klinikum Steglitz, Freie Universitaet Berlin, Berlin, F.R.G.

(14)

xvi Contributors

R.D. Hockett, Jr. University of Minnesota, Minneapolis, Minnesota

55455, U.S.A.

Peter Hokland The University Department of Medicine and

Hematol-ogy, Aarhus Amtssygehus, Denmark DK-8000

Keizo Horibe Human Immunogenetics Laboratory, Memorial

Sloan-Kettering Cancer Center, New York, New York 10021, U.S.A.

J.C. Horowitz Division of Tumor Immunology, Dana-Farber Cancer

In-stitute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Donald R. Howard Terry Fox Laboratory, B.C. Cancer Research

Cen-tre, Vancouver, British Columbia, Canada

W. Hunstein Medizinische Universitats-Poliklinik, D-6900 Heidelberg,

F.R.G.

Yoshifumi Ishii Department of Pathology, Sapporo Medical College, S 1

WI7 Sapporo 060, Japan

G.D. Johnson Department of Immunology, University of Birmingham,

Medical School, Birmingham B15 2TJ, U.K.

D.B. Jones University Department of Pathology, General Hospital,

Southampton S09 4XY, U.K.

David G. Jose Immunogenetics Research Unit, Cancer Institute,

Mel-bourne, Australia 3000

Lawrence K.L. Jung Cancer Research Program, Oklahoma Medical

Re-search Foundation, Oklahoma City, Oklahoma 73104, U.S.A.

John H. Kersey University of Minnesota, Minneapolis, Minnesota

55455, U.S.A.

M. Khan Department of Immunology, University of Birmingham,

Medi-cal School, Birmingham B 15 2TJ, United Kingdom

S. Kiesel Medizinische U niversitats-Poliklinik, D-6900 Heidelberg,

F.R.G.

Kokichi Kikuchi Department of Pathology, Sapporo Medical College,

SI W17 Sapporo 060, Japan

James Kiwanuka Pediatric Branch, Clinical Oncology Program,

Divi-sion of Cancer Treatment, National Cancer Institute, National Insti-tutes of Health, Bethesda, Maryland 20205, U.S.A.

Jeroen Knops Institute fUr Immunologie und Genetik, Deutsches

Krebs-forschungszentrum, D-6900 Heidelberg, F.R.G.

Robert W. Knowles Human Immunogenetics Laboratory, Memorial

Sloan-Kettering Cancer Center, New York, New York 10021, U.S.A.

Yasuo Kokai Department of Pathology, Sapporo Medical College, S 1

WI7 Sapporo 060, Japan

Norbert Kraft Nephrology Department, Prince Henry's Hospital,

Mel-bourne, Australia

Bernhard Kubanek Red Cross Blood Bank Uim, Department of

(15)

Contributors XVlI

H. Ladyman Department of Haematology, John Radcliffe Hospital, Ox-ford OX3 9DU, U.K.

F. Lancelin Groupe Universitaire de Recherche en Immunologie Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

Gilles J. Lanzon Department of Pediatrics and the Tom Baker Can-cer Centre, University of Calgary, Calgary, Alberta, Canada T2N 4Nl

Thierry Lavabre-Bertrand Service des Maladies du Sang, C.H. U., Montpellier, France

A.M. Lebacq-Verheyden Unite de Recherches sur les Maladies du Sang, Universite Catholique de Louvain, Brussels, Belgium

Tucker W. LeBien Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, U.S.A. R. Leblay Groupe Universitaire de Recherche en Immunologie

Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U. Rennes, France

Jeffrey A. Ledbetter Immunobiology Group, Genetic Systems Corpora-tion, Seattle, Washington 98121, U.S.A.

Grace T.H. Lee Immunogenetics Research Unit, Cancer Institute, Mel-bourne, Australia 3000

N.R. Ling Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.

B. Michael Longenecker Department ofimmunology, University of Al-berta, Edmonton, AlAl-berta, Canada T6G 2H7

W.D. Ludwig Abt. Hamatologie, Klinikum Steglitz, Freie Universitat Berlin, Berlin, F.R.G.

I.C.M. MacLennan Department of Immunology, University of Birming-ham, Medical School, Birmingham B15 2TJ, U.K.

Ian T. Magratb Pediatric Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Abby L. Maizel Department of Pathology, Section of Pathobiology, The University of Texas Cancer Center, Houston, Texas 77030, U.S.A.

Gerald E. Marti Hematology Service, Clinical Pathology Department, National Institutes of Health, Bethesda, Maryland 20205, U.S.A. M. Marty Groupe Universitaire de Recherche en Immunologie

Fonda-mentale et Appliquee, Service de Medecine Interne, Departement d'Hematologie, C.H.U., Rennes, France

D.Y. Mason Department of Haematology, John Radcliffe Hospital, Ox-ford OX3 9DU, U.K.

Robert T. McCormack Department of Laboratory Medicine/Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

(16)

xviii Contributors

G. Merdrignac Groupe Universitaire de Recherche en Immunologie Fondamentale et Appliquee, Service de Medecine Interne, Departe-ment d'Hematologie, C.H.U., Rennes, France

Karin Meyer The University Department of Medicine and Hematology,

Aarhus Amtssygehus, Denmark DK-8000

Patricia M. Michael Immunogenetics Research Unit, Cancer Institute,

Melbourne, Australia 3000

Jordi Mila Servicio de Inmunologfa, Hospital Clinic i Provincial, 08036

Barcelona, Spain

Gerhard Moldenhauer Institut fUr Immunologie und Genetik, Deutsches

Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

Frank Momburg Institut fur Immunologie und Genetik, Deutsches

Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

John Morgan Department of Pathology, Section of Pathobiology, The

University of Texas Cancer Center, Houston, Texas 77030, U.S.A.

Marion Moxley Medical Research Council, Clinical and Population

Cy-togenetics Unit, Western General Hospital, Edinburgh, U.K.

Lee M. Nadler Division of Tumor Immunology, Dana-Farber Cancer

Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

P .D. Nathan Department of Immunology, University of Birmingham,

Medical School, Birmingham B15 2TJ, U.K.

Leonard M. Neckers Laboratory of Pathology, National Cancer

Insti-tute, National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

G. Pallesen University Institute of Pathology, Kommunehospitalet,

DK-8000 Aarhus C, Denmark

Edward Park Division of Tumor Immunology, Dana-Farber Cancer

In-stitute, Boston, Massachusetts 02115, U.S.A.

Carlo Parravicini Fifth Department of Pathology, University of Milan,

Milan, Italy

Antonio Pezzutto Medizinische Universitats-Poliklinik, D-6900

Heidel-berg, F.R.G.

Glenn R. Pilkington Immunogenetics Research Unit, Cancer Institute,

Melbourne, Australia 3000

Samuel J. Pirruccello Department of Laboratory Medicine/Pathology,

University of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

Stefania Pittaluga Laboratory of Pathology, National Cancer Institute,

National Institutes of Health, Bethesda, Maryland 20205, U.S.A.

Jeffrey L. Platt Department of Laboratory Medicine/Pathology,

Uni-versity of Minnesota Medical School, Minneapolis, Minnesota 55455, U.S.A.

Philippe Poncelet Immunotoxin Project, Research Center Clin-Midy,

(17)

Contributors xix

Anand Raghavachar Red Cross Blood Bank Ulm, Department of Trans-fusion Medicine, University of Ulm, D-7900 Ulm, F.R.G.

A.M. Ravoet Unite de Recherches sur les Maladies du Sang, Universite Catholique de Louvain, Brussels, Belgium

Frances Rawle ICRF Human Tumor Immunology Group, School of Medicine, University College London, London 'YClE 6JJ, U.K. H. Riehm Abt. Padiatrie VI, Medizinische Hochschule Hannover,

Han-nover, F.R.G.

John T. Sandlund Pediatric Branch, Clinical Oncology Program, Divi-sion of Cancer Treatment, National Cancer Institute, National Insti-tutes of Health, Bethesda, Maryland 20205, U.S.A.

Volker Schirrmacher Institute of Immunology and Genetics, German Cancer Research Center, D-6900 Heidelberg, F.R.G.

Stuart F. Schlossman Division of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, U.S.A.

Reinhard Schwartz Institut fUr Immunologie und Genetik, Deutsches Krebsforschungszentrum, D-6900 Heidelberg, F.R.G.

Geraldine Shu Immunobiology Group, Genetic Systems Corporation, Seattle, Washington 98121, U.S.A.

Bruce Slaughenhoupt Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, U.S.A.

C.M. Steel Medical Research Council Clinical and Population Cytoge-netics Unit, Western General Hospital, Edinburgh, U.K.

Tsuyoshi Takami Department of Pathology, Sapporo Medical College, SI W17 Sapporo 060, Japan

Fumio Takei Terry Fox Laboratory, B.C. Cancer Research Centre, Vancouver, British Columbia, Canada

Takashi Takei Department of Pathology, Sapporo Medical College, S 1 W17 Sapporo 060, Japan

Thomas F. Tedder Cellular Immunobiology Unit, Tumor Institute, Uni-versity of Alabama in Birmingham, Birmingham, Alabama 35294, U.S.A.

E. Thiel Institute fUr Haematologie, Miinchen, F.R.G.

David A. Thorley-Lawson Departments of Pathology and Medicine, . Tufts University School of Medicine, Boston, Massachusetts 02115, U.S.A.

Jane B. Trepel Laboratory of Pathology, National Cancer Institute, Na-tional Institutes of Health, Bethesda, Maryland 20205, U.S.A. Ramon Vilella Servicio de Imnmunologfa, Hospital Clinic i Provincial,

08036 Barcelona, Spain

Jordi Vives Servicio de Inmunologfa, Hospital Clinic i Provincial, 08036 Barcelona, Spain

L. Walker Department of Immunology, University of Birmingham, Medical School, Birmingham B15 2TJ, U.K.

(18)

xx Contributors

Janis J. Weis Department of Medicine, Harvard Medical School,

De-partment of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, Massachusetts 02115, U.S.A.

P. Wernet Medizinische Universitats-Klinik, Tiibingen, F.R.G.

James G. White University of Minnesota, Minneapolis, Minnesota

55455, U.S.A.

D.H. Wright University Department of Pathology, General Hospital,

Southampton S09 4XY, U.K.

Hiroo Yuasa Department of Pathology, Sapporo Medical College, SI

WI7 Sapporo 060, Japan

Theodore F. Zipf Faculty of Medicine, University of Calgary, Calgary,

Alberta, Canada T2N 4N 1

Heddy Zola Flinders Medical Centre and Flinders University of South

References

Related documents

The Tanzania ICT Technology Park which is a public and private partnership between the Government of Tanzania and SEACOM is aiming to house universities for

Međimursko veleučilište u Čakovcu 26 Osnovom za plaćanje FINI smatra se: „rješenje o ovrsi, rješenje o osiguranju, zadužnica, nalog za pljenidbu u postupku

Chapter 2 explains in detail the methodology followed; chapter 3 presents the legal background of copyright protection in Peru, as well as an international comparison; chapter 4

Specialist Services HR Partners/Staff Development HR Partners/Staff Development HR Partners HR Partners/ Employment Services HR Partners/ Staff Development HR Partners

At the moment several strategies have been applied to influence probiotic survival during gastrointestinal tract passage, including adjustment of growth conditions

Ramey and Ramey (1995) introduced a non-linear model relating volatility to growth.. The solution of this model by generalised computer algorithms for non-linear maximum

In these systems, direct excitons inside indi- vidual quantum wells are coupled to an optical mode and impart the effect of their Coulomb interaction as an effec- tive Kerr

The central question of our study is: How do professionals involved in public – private partnerships in Canada, the Netherlands and Denmark perceive the (ideal) governance